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demonstrate acceptable in vivo viability and no evidence of
neoantigen formation_3133 2228..2236
Jose A. Cancelas, Neeta Rugg, P. Gayle Pratt, D. Nicole Worsham, Joan C. Pehta, Kate Banks,
Robertson D. Davenport, and W. John Judd
BACKGROUND: Transmission of variant Creutzfeldt-
Jacob disease (vCJD) is a major concern in blood
transfusion. The P-Capt filter has been shown to
remove around 4 log ID50 prion infectivity from prion-
spiked human red blood cells (RBCs).
STUDY DESIGN AND METHODS: Two independent,
single-center, randomized, open-label studies were
designed to analyze the safety of P-Capt–filtered RBCs.
RBCs prepared from leukoreduced whole blood from 43
eligible subjects were randomly assigned to P-Capt fil-
tration and/or storage in plasma or SAGM and stored
for 28 or 42 days. Stored RBCs were analyzed for in
vivo 24-hour recovery, hemolysis, metabolic variables,
blood group antigen expression, neoantigen formation,
and safety after autologous infusion.
RESULTS: Mean P-Capt filtration times for leukore-
duced RBCs were 41 (SAGM) to 51 (plasma) minutes.
Thirteen of 14 subjects receiving P-Capt–filtered RBCs
had 24-hour RBC recoveries of 75% or more after
42-day storage, with a mean hemolysis of less than
0.6%. No loss of RBC antigen expression or formation
of neoantigens was observed. In both studies, RBCs
had white blood cell counts of less than 1 ¥ 106/unit
after leukofiltration. P-Capt prion filtration provided an
additional greater than 0.8 log leukoreduction. No
serious or unexpected adverse events were observed
after infusion of P-Capt–filtered full-volume RBC units.
CONCLUSIONS: P-Capt–filtered, stored RBCs demon-
strated acceptable viability and no detectable neoanti-
gen expression, immunogenic responses. or safety
issues after infusion of a complete unit. The additional
filtration time and modest reduction in RBC content are
within acceptable levels for implementation in countries
with transfusion transmission of vCJD.
H
uman transmissible spongiform encephalo-
pathies (TSEs) are a group of related diseases
that include kuru and sporadic and variant
Creutzfeldt-Jakob Disease (vCJD).1 vCJD, a
disease with a clinical course and neurologic profile
distinct from sporadic CJD, is a zoonosis derived from
bovine spongiform encephalopathy (“mad cow dis-
ease”).2,3 Although the incidence of vCJD has waned
in the past few years, the number of individuals infected
with vCJD in the United Kingdom was estimated by
survey of surgically removed tissues to be around 100 per
million in the population of age-related high risk,4,5
far greater than the incidence observed, and forewarns
that blood donations from asymptomatic individuals
may present a serious threat of human-to-human
transmission.6
Sixty-six recipients of blood donated by persons who
later died of vCJD have been identified. Of the 19 recipi-
ents who lived long enough to present evidence of vCJD,
four cases of transfusion-transmitted vCJD have been
diagnosed either at autopsy or clinically.7,8 This is consis-
tent with a transmission rate of at least 20%.9 In nonhu-
man primates, transmissibility of TSE by transfusion
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appears to be as high as the oral route.10 Non–white blood
cell (WBC)-bound prion protein infectivity is not removed
by leukofiltration, and therefore leukoreduction alone
may have little impact on transmission risk.11,12
Although testing of individual donations is desirable,
the technical challenges in developing a sensitive test to
identify prion protein remain formidable,13 and although
a new assay for CJD detection in cerebrospinal fluid of
patients has been recently reported,14 at this point in time,
there is no credible assay for vCJD detection in blood
donors. The lack of success with leukoreduction, the
inherent difficulties in developing chemical-based
pathogen inactivation protocols for red blood cell (RBC)
containing products that would be effective on prion
infectivity, and the inability thus far to develop a method
to detect prion infectivity in blood means prion removal is
the only practical solution to further reduce the risk of
transfusion transmission. An appropriately designed and
validated prion filtration strategy might also provide
greater protection from these low-titer, long-incubating
agents than is theoretically possible by diagnostic
strategies.
A prion-specific affinity resin developed by Pathogen
Removal and Diagnostic Technologies, Inc. for the selec-
tive adsorption of prions was incorporated into a filter
device format, P-Capt, by Macopharma (Tourcoing,
France), which was approved for use in the European
Union (CE marked) in 2006. The resin, integrated into the
prion filter, has been shown to remove approximately 4 log
ID50 of prion infectivity from human blood spiked with a
hamster brain homogenate from symptomatic hamsters
previously infected with 263K scrapie, a commonly used
model to test prion infectivity.15 The resin also demon-
strated the ability to remove endogenous infectivity from
hamster leukoreduced RBCs to below the limit of detec-
tion of the bioassay used to determine the infectivity
titer.11 RBC storage variables after leukoreduced RBCs
were filtered with the P-Capt prion filter and then stored
with either plasma-CPD or SAGM to outdate have been
evaluated.16-18 All of the final variables (hemoglobin [Hb]
g/unit, hematocrit [Hct], residual WBCs, total volume) as
well as end of shelf life product variables (hemolysis,
adenosine 5′-triphosphate [ATP], 2,3-diphosphoglycerate
acid [2,3-DPG], potassium, and pH) were within the UK
and Council of Europe Guidelines.19,20 No effects on
complement or coagulation factor activation were
observed, and no platelet (PLT) activation was identified.21
These results indicate that RBC stability is not adversely
affected by exposure to the P-Capt prion filter. More
recently, the use of the P-Capt prion filter has been shown
to have no detrimental effect on the in vitro variables of
RBC quality, nor did its use appear to induce any relevant
immunohematologic changes, although it did result in a
loss of Hb. Despite this loss, the units remained within UK
specifications throughout storage.18
Here, we report two studies designed to assess the
effects of prion filtration on RBCs stored in nonadditive or
additive solution by analysis of in vivo recovery, neoanti-
genicity, in vitro biochemical, and hematologic stability
after 28 days in CPD-plasma or 42 days in SAGM solution
and in vivo safety and neoantigenicity after infusion.
MATERIALS AND METHODS
Two independent, single-center, randomized, open-label
studies were performed under the authorization of the
institutional review board at the University of Cincinnati.
All subjects gave written informed consent and were eli-
gible to donate according to the criteria of the Food and
Drug Administration and the AABB (with the exception of
travel-related deferrals). After screening, all subjects had 1
unit of whole blood (WB; 450 mL  10%) drawn using a
CPD-SAGM collection set (DQE 6282LB, Macopharma)
with an integral WB WBC removal filter (LST2-WB).
The primary endpoint of the chromium-51 (51Cr)–
labeled RBC 24-hour recovery study (Study 1) was to
examine the in vivo 24-hour recovery after infusion of
autologous RBCs that had been filtered using the P-Capt
prion filter and document that there were no more than
20% of the components with an in vivo 24-hour recovery
of less than 75%.
In Study 1, after WBC filtration, subjects were ran-
domized into one of four cohorts:
• Cohort 1: P-capt prion-filtered blood; 28-day storage
in plasma (P-Capt-plasma)
• Cohort 2: non–P-capt prion-filtered blood; 28-day
storage in plasma (control-plasma)
• Cohort 3: P-capt prion-filtered blood; 42-day storage
in SAGM (P-Capt-SAGM)
• Cohort 4: non–P-capt prion-filtered blood; 42-day
storage in SAGM (control-SAGM)
A second filtration step using the P-Capt prion filter
(PSE 3080XB, Macopharma) was performed immediately
thereafter in Cohorts 1 and 3. An aliquot from the pre-
pared RBC units was taken on Days 0, 14, and 27 and
tested for biochemical and hematologic variables. Results
of prion-filtered units were compared to control (non–
prion-filtered). All the processes were performed within 8
hours of blood collection. Sterility of the stored RBC units
was tested 5 to 10 days before reinfusion of an aliquot of
51Cr-radiolabeled RBCs. The blood was stored under
normal blood bank conditions (1-6°C).
In the immunohematologic study (Study 2), after
WBC filtration, blood units were stratified based on ABO
blood group and randomly assigned to one of two cohorts:
• Cohort 1: P-Capt prion-filtered blood; 28-day storage
of RBCs in plasma
• Cohort 2: P-Capt prion-filtered blood; 42-day storage
of RBCs in SAGM
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This process was designed so that for each cohort,
there would be a minimum of two subjects with blood
group A, one with blood group B, and two with blood
group O. Half of the subjects had SAGM added to their
RBCs and the other half had plasma added to their RBCs
followed by another filtration step using the P-Capt prion
filter (PSE 3080XB, Macopharma). Samples were drawn for
testing before leukofiltration (baseline), before prion fil-
tration, at the start of storage, and after storage. Blood was
stored for either 28 days (plasma) or 42 days (SAGM)
under normal blood bank conditions (1-6°C). Sterility of
the stored RBC units was tested 5 to 10 days before rein-
fusion. At the end of storage and before reinfusion, each
unit was inspected for any signs of unusual hemolysis or
discoloration, and sample was drawn to evaluate changes
from the baseline sample. The entire autologous RBC unit
was then reinfused into the subjects. Follow-up consisted
of the evaluation of safety events and laboratory assays
(including evidence of neoantigenicity) for 6 weeks after
infusion.
For both Study 1 and Study 2, analysis of hematology,
spun Hct, postfiltration WBC count, plasma Hb, sodium,
potassium, glucose, lactate, pH, 2,3-DPG, and ATP were
performed according to standard procedures and/or
manufacturer’s instructions. For both studies, bacterial
cultures were performed on all units during the last week
of storage.
WBC content
Remaining WBC content was determined by high sensitiv-
ity fluorescence-activated cell sorting analysis of pro-
pidium iodide–positive events using calibrated beads
(Becton Dickinson, San Jose, CA).22
24-hour recovery of 51Cr-labeled RBCs (Study 1)
On Day 28 or 42, each unit was inspected for any signs of
unusual hemolysis or discoloration indicative of bacterial
growth. Each unit was well mixed by hand (1 min), and
approximately 15 mL of the RBCs was labeled with
approximately 15 (10-20) mCi 51Cr using standard tech-
niques.23,24 The labeling agent, sodium chromate 51Cr, was
mixed aseptically with the RBCs at room temperature
for 30 minutes and washed once with a double volume of
saline. An aliquot of the final volume was reserved as a
standard, and the remaining labeled cells (approx. 10 mL)
were injected into a free-flowing peripheral vein. Samples
(5 mL each) were taken from a contralateral vein at 5, 7.5,
10, 12.5, 15, 20, and 60 minutes, as well as at 24 hours. The
samples were counted in a gamma counter to determine
51Cr activity. The activity of the samples from the first 15
minutes was back-extrapolated to determine T0. A total
of 27 subjects were eligible and evaluated. One recovery,
from a subject belonging to the nonfiltered 42-day SAGM
group (Study 1, Cohort 4), could not be evaluated due to
difficulties with venous access.
Immunohematologic studies (Study 2)
The expression of C, e, and k antigens was determined in
agglutination tests with monoclonal reagents (Hemo Bio-
science, Durham, NC). The expression of D, E c, K, Fya,
Fyb, S, and s antigens was determined by gel technique
using polyclonal reagents (Hemo Bioscience) prediluted
in AB serum to a titer of 4 to 8 versus single-dose RBCs.
Reactions were graded and scored using the method of
Marsh and Jenkins.25 Expression of Band 3 and CD47
antigens was determined by flow cytometry using fluo-
rescein isothiocyanate (FITC)-conjugated antibody to
Band 3 (BRIC-6, International Blood Group Reference
Laboratory, Bristol, UK) and CD47 (MIMA-49, New York
Blood Center, New York, NY) with FITC-conjugated goat
anti-mouse immunoglobulin (Ig)G (Abcam, Cambridge,
MA). Direct antiglobulin tests (DAT) were performed
using tube technique with polyclonal reagent (anti-IgG
plus C3, Ortho Clinical Diagnostics, Raritan, NJ). Gel
tests for unexpected antibodies and DAT were performed
on pretransfusion and on Day 42 posttransfusion
samples with Group O R1R1, R2R2, and rr reagent
RBCs. In addition, these samples were tested by gel
technique against P-Capt prion filtered RBCs. Tests
between the prion filtered RBCs and 12 randomly
selected AB plasma units were also performed using the
gel technique.
Statistical analysis
Fisher’s exact test or paired t test (SAS Version 8.20 or
higher, SAS Institute, Inc., Cary, NC) were used for statis-
tical analyses. Unless otherwise specified, all statistical
tests were conducted using a two-sided alternative
hypothesis and had a significance level of at least 0.05.
RESULTS
Demographics and baseline characteristics
In Study 1, 33 subjects were screened and 29 were
enrolled. One subject withdrew from the study due to an
inability to return within the time frame required for rein-
fusion, this subject was replaced. The mean age of all sub-
jects was 39.2  13.4 years. There were no significant
differences in demographic variables between the cohorts
in baseline vital signs, screening Hct, or laboratory vari-
ables. In Study 2, 16 subjects were screened, 14 were
enrolled, and seven were assigned to each treatment
group. The mean age of all subjects was 44.1  12.3 years.
Distribution of donors according to their ABO group was
as follows: five blood group A (two SAGM and three
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plasma), two blood group B (one each SAGM and plasma),
and seven blood group O (four SAGM and three plasma).
For both studies, all inclusion-exclusion criteria were met
for each subject.
WBC reduction and RBC yield
For both studies, all units had WBC counts of less than
5 ¥ 106/unit after leukofiltration. The mean prion filtration
time was 41.8  6.2 and 42.6  16.2 minutes for the SAGM
groups on Studies 1 and 2, respectively, and 41.4  16.2
and 51.4  16.4 minutes for the plasma groups in Studies
1 and 2. For Study 1, the mean WBC count after leukofil-
tration was 0.11  0.09 cells/mL in the P-Capt 28-day
storage group and 0.16  0.19 cells/mL in the P-Capt
42-day storage group. After prion filtration the WBC
counts were 0.04  0.04 and 0.01  0.02 cells/mL, respec-
tively. This resulted in an 86.7% reduction (p = 0.0004) in
the P-Capt 28-day and a 94.7% reduction (p = 0.0001) in
the P-Capt 42-day group. For Study 2, the WBCs remaining
after prion filtration were 0.04  0.04 cells/mL (83.9%,
p = 0.001) in the SAGM group and 0.18 cells/mL (93.1%,
p < 0.001) in the plasma group.
We next analyzed the volume of RBCs after filtration.
It should be noted that 40 mL of the SAGM solution in
the prion filter remains in the final product. For both
studies, the mean starting volume was similar across
the four cohorts, as were the mean volumes of the
units before prion filtration, if applicable (Table 1). The
mean volume of RBCs recovered after prion filtration, for
plasma- and SAGM-containing products, after correction
for the additional fluid in the prion filter was 86.2%, and
87.0%, of the recoveries of the corresponding non–prion-
filtered, WBC-filtered RBC products, respectively. Despite
this loss of Hb (Table 1), all units had 40 g Hb/unit or
more at the time of storage, which is consistent with the
UK specifications for leukoreduced units.
Poststorage biochemical variables
There were no significant changes in mean RBC content,
Hb level, PLT numbers, and spun Hct over time in the
prion-filtered units stored in either SAGM or plasma (data
not shown). The results of testing for Hct, pH, and ATP
showed significant decreases from the time of initial
storage to immediately before reinfusion for both SAGM-
and plasma-stored samples (Table 2). In all groups, the
level of 2,3-DPG decreased after storage, as expected, to
less than 1 mmol/g Hb (data not shown). Mean glucose
consumption ranged from 35% to 69%, mean lactate con-
centration increased from 6.1 to 15.8-fold, and mean
potassium increased from 12.8- to 29.9-fold (data not
shown) without any significant difference between
P-Capt–filtered and control units and with values within
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solution used. The percentage of hemolysis showed a sig-
nificant increase during storage that was within reported
ranges for 28- and 42-day storage in CPD plasma and
SAGM, respectively (Table 2). All units had 0.8% or less
hemolysis at baseline. On the day before the end of storage
4 of 15 units in the P-Capt SAGM cohorts had a value of
more than 0.8% and 2 of 15 units had a value higher
than 1%.
In vivo 24-hour 51Cr-labeled RBC recovery: Study 1
In Study 1, one subject in Cohort 4 (SAGM control arm)
was unable to complete the RBC recovery procedure due
to difficulties with venous access. The percentage of sub-
jects with an RBC recovery of 75% or more at 24 hours was
87.5% in both the prion-filtered and non–prion-filtered
28-day plasma storage groups, and 100% in the prion-
filtered SAGM and 80% in the control SAGM arm (Table 3).
There were no significant differences in the number of
subjects with an RBC recovery of 75% or more at 24 hours
among the four cohorts (Table 3).
Immunohematologic studies: Study 2
In the neoantigenicity analysis performed in Study 2, no
major differences were seen between pre- and post–prion
filtration RBC antigen scores (Figs. 1 and 2) or in Band 3
and CD47 percentage of positive cells or mean fluorescent
intensity (Table 4). All pre- and 6-week posttransfusion
DATs and antibody screens were negative. No reactivity
was seen with AB plasma and prion-filtered (and
non–prion-filtered) control cells. Finally, tests to detect
antibody formation to prion-filtered RBCs, performed
between control prion-filtered RBCs from random group-
compatible donors and postinfusion subject plasma, were
nonreactive.
Infusion tolerability and adverse events
For Study 1, there were no serious adverse events
reported. There were 14 adverse events reported in eight
subjects (11 events in the P-Capt arms and three in the
control arms). One of the 14 total adverse events was con-
sidered as “unlikely related” to study treatment (sinusitis),
the remaining 13 events were considered to be “unrelated”
to the study treatment. The most frequently reported
adverse events were headache (¥6), sinusitis (¥2), dyspep-
sia (¥2), and dysmenorrhea (¥2). There was one report
each of rhinitis and pain. There were five events classified
as Grade 2 (dysmenorrhea [¥2], headache [¥2], and
myalgia), all of which occurred in two subjects randomly
assigned to Cohort 3 (P-Capt filter-SAGM), and none were
thought to be related to study treatment. The remaining
nine events were classified as Grade 1. There were no
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reported and the donation of the WB unit or the reinfusion
of the stored, radiolabeled RBC. The time lapse between
the withdrawal of the WB unit and the onset of the adverse
event ranged from 2 to 43 days, and the time between the
RBC reinfusion and the onset of the adverse event ranged
from 1 to 40 days. All vital signs remained stable during
infusion. There were no serious adverse
events reported and all bacterial cul-
tures were sterile after 5 days of incuba-
tion. There were no significant changes
before or after infusion in mean systolic
or diastolic blood pressure, pulse, or
temperature. None of the values for
these variables were outside of the
normal range after reinfusion.
For Study 2, there were five Grade 1
(mild and generally transient deviation
from typical or normal clinical course)
adverse events (three in the SAGM
group and two in the plasma group)
reported in four subjects, headache
(¥2), sore throat (pharyngitis), knee pain
(arthralgia), and myalgia. All of the
events occurred either 20 or more days
before infusion (arthalgia and myalgia)
or 30 or more days after infusion. All
vital signs remained stable during
infusion. There were no serious adverse
events reported and all bacterial cul-
tures were sterile after 5 days of incuba-
tion. There were no significant changes
before or after infusion in mean systolic
or diastolic blood pressure, pulse, or
temperature. None of the values for
these variables were outside of the
normal range after reinfusion.
DISCUSSION
The P-Capt prion filter is a sterile dock-
able filter for the removal of prions from
leukoreduced RBCs. The P-Capt filter
was designed to help further reduce the
risk of transmission of vCJD through
transfusion of RBC units by the selective adsorption of
prions. In the filter, ligands specific for prion proteins are
covalently attached to a resin. The resin is impregnated
between nonwoven media, which is then integrated and
placed in an outer polyvinylchloride housing to form the
P-Capt prion filter.








(n = 5†) p value*
Mean  SD 85.1  6.1 83.0  9.3 0.62 84.0  6.3 78.6  2.9 0.10
Range 74.6-93.8† 65.9-93.2† 78.7-97.4 73.6-81.1†
Percentage with recovery  75%
No 1 (14.3%) 1 (14.3%) 1.0 0 1 (20%) 0.38
Yes 6 (85.7%) 6 (85.7%) 8 (100%) 4 (80%)
* p value based on Fisher’s exact test.
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Fig. 1. RBC antigen typing scores: stored prion-filtered and non–prion-filtered
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Fig. 2. RBC antigen typing scores: stored prion-filtered and non–prion-filtered
(controls) from heterozygous subjects.
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Although standard leukoreduction has been demon-
strated to remove WBC-associated TSE infectivity in WB
collected and pooled from scrapie-infected hamsters,
only 42% to 72% of the total blood-borne infectivity is
removed.14,18 Studies evaluating the effectiveness of the
P-Capt prion filter have demonstrated a greater than
99.9% (>3 log) reduction of infectivity in human RBCs
spiked with a hamster-derived scrapie infected homoge-
nate.15 In another study, none of 100 hamsters inoculated
with P-Capt prion-filtered leukoreduced WB from TSE-
infected animals became infected, while 15 of 99 hamsters
inoculated with leukoreduced blood from TSE-infected
animals that had not been treated with the P-Capt prion
filter contracted TSE infections from the contaminated
blood.11 Additionally, the removal of endogenous blood-
borne infectivity, a more representative test of perfor-
mance, was demonstrated to remove more than 1.2 log of
infectivity, which is below the detection limit of the most
sensitive bioassay systems available for the measurement
of prion infectivity.15
Overall, in this study, prion-filtered units had an
approximately 15% lower content of RBCs than non–
prion-filtered units, while maintaining Hb at or above
40 g/unit. Hemolysis was less than 0.8% for all units stored
in plasma for 28 days, but was higher than 0.8% in 4 of 15
units and more than 1% in 2 of 15 units stored in SAGM.
The increased hemolysis of these 42-day-stored units may
be a result of the additional manipulation during storage
where sampling for blood cultures was required before in
vivo administration. A recent study on 272 P-Capt–filtered
units that had been stored unmanipulated for up to 42
days in SAGM has shown that this method may meet the
UK specifications.18
The primary endpoint of Study 1 was to examine the
24-hour recovery after infusion of radiolabeled autolo-
gous RBCs after filtration with the P-Capt prion filter and
to document that there were no more than 20% compo-
nents with a recovery of less than 75%. Across all sub-
jects, the mean RBC recovery was 83%, 84.5% in all
subjects in the P-Capt groups and 81.2% in all subjects in
the non–P-Capt groups. There were no significant differ-
ences in RBC recovery between the P-Capt 28-day
(85.1%) and the non–P-Capt 28-day groups (83.0%) or
between the P-Capt 42-day (84.0%) and non–P-Capt
42-day (78.6%) groups.
The percentage of subjects with RBC recovery of 75%
or more at 24 hours was 87.5% in both 28-day treatment
groups, 100% in the P-Capt 42-day treatment group, and
80% in the non–P-Capt 42-day group. There were no sig-
nificant differences in the number of subjects with RBC
recovery of 75% or more at 24 hours between the P-Capt
28-day group (85.7%; 95% confidence interval [CI], 59.8 to
[-100]) and the non–P-Capt 28-day group (85.7%; 95% CI,
59.8 to [-100]; p = 1.00), nor between the P-Capt 42-day
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groups (80%; 95% CI, 44.9 to [-100]; p = 0.38). Therefore,
the primary endpoint was met.
In Study 2, a full unit of prion-filtered RBCs was well
tolerated after autologous infusion without any relevant
adverse events. Analysis showed an absence of changes
in RBC antigens after storage, and DAT and antibody
screening for RBC antigens or neoantigens 6 weeks after
infusion of autologous prion-filtered RBCs were negative.
These results are in line with the data from Cahill and
colleagues16 who found no significant adverse events in a
group of 20 patients transfused with 1 unit, including
six who received transfusion of a second prion-filtered
unit. Additional studies are required to rule out the
development of antibody formation after repeated infu-
sions and analysis of their impact on the RBC recovery
in vivo.
In conclusion, the use of the P-Capt prion filter
resulted in an adequate safety profile with acceptable
storage variables assessed by in vivo methods and no indi-
cation of the development of neoantigenicity after P-capt
filtration and reinfusion of 1 complete unit of autologous
RBCs in normal volunteers.
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